Zobrazeno 1 - 2
of 2
pro vyhledávání: '"Colleen Krohn"'
Autor:
Colleen Krohn, Zhongkai Shi, Hadn Africa, Gregory D. Hussey, Bruce McClain, Yolande Brown, Hassan Mahomed, Søren T. Hoff, Lebohang Makhethe, Margaret A Snowden, Hennie Geldenhuys, Mark Hatherill, Elisma Schoeman, Angelique Kany Kany Luabeya, Thomas J. Scriba, Sara Suliman, Cheryl L. Day, Ingrid Kromann, Erica Smit, Michele Tameris, E. Jane Hughes, Peter Bang, Benjamin M. Kagina, Peter Andersen, Willem A. Hanekom
Publikováno v:
Vaccine. 33:4130-4140
Background H56:IC31 is a candidate tuberculosis vaccine comprising a fusion protein of Ag85B, ESAT-6 and Rv2660c, formulated in IC31 adjuvant. This first-in-human, open label phase I trial assessed the safety and immunogenicity of H56:IC31 in healthy
Externí odkaz:
https://explore.openaire.eu/search/publication?articleId=doi_dedup___::4d4d0e6d7b77f74bfee22748910708f9
https://doi.org/10.1016/j.vaccine.2015.06.051
https://doi.org/10.1016/j.vaccine.2015.06.051
Autor:
Bruce McClain, Wendy Whatney, Angelique Luabeya Kany Kany, Jerald C. Sadoff, Nazma Mansoor, Hennie Geldenhuys, Marwou de Kock, Mark Hatherill, Maria Grazia Pau, Brian Abel, David A. Hokey, Jacqueline G. Benko, Colleen Krohn, Margaret A Snowden, Ashley Veldsman, Jenny Hendriks, Gregory D. Hussey, Hassan Mahomed, Thomas J. Scriba, Michele Tameris, Hadn Africa, Benjamin M. Kagina, Macaya Douoguih, Willem A. Hanekom, Jane Hughes
Publikováno v:
Vaccine. 32:5908-5917
Background Efforts to reduce risk of tuberculosis disease in children include development of effective vaccines. Our aim was to test safety and immunogenicity of the new adenovirus 35-vectored tuberculosis vaccine candidate AERAS-402 in infants, admi
Externí odkaz:
https://explore.openaire.eu/search/publication?articleId=doi_dedup___::7ca584ec072300b42556a291c1aecbb2
https://doi.org/10.1016/j.vaccine.2014.09.001
https://doi.org/10.1016/j.vaccine.2014.09.001